Cargando…

Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

PURPOSE: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. METHODS: In the SELECT BC t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiroiwa, T., Fukuda, T., Shimozuma, K., Mouri, M., Hagiwara, Y., Doihara, H., Akabane, H., Kashiwaba, M., Watanabe, T., Ohashi, Y., Mukai, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/
https://www.ncbi.nlm.nih.gov/pubmed/27517267
http://dx.doi.org/10.1007/s11136-016-1388-1
_version_ 1782504326120341504
author Shiroiwa, T.
Fukuda, T.
Shimozuma, K.
Mouri, M.
Hagiwara, Y.
Doihara, H.
Akabane, H.
Kashiwaba, M.
Watanabe, T.
Ohashi, Y.
Mukai, H.
author_facet Shiroiwa, T.
Fukuda, T.
Shimozuma, K.
Mouri, M.
Hagiwara, Y.
Doihara, H.
Akabane, H.
Kashiwaba, M.
Watanabe, T.
Ohashi, Y.
Mukai, H.
author_sort Shiroiwa, T.
collection PubMed
description PURPOSE: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. METHODS: In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. RESULTS: The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748 [0.722–0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). CONCLUSIONS: Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm.
format Online
Article
Text
id pubmed-5288429
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-52884292017-02-16 Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial Shiroiwa, T. Fukuda, T. Shimozuma, K. Mouri, M. Hagiwara, Y. Doihara, H. Akabane, H. Kashiwaba, M. Watanabe, T. Ohashi, Y. Mukai, H. Qual Life Res Article PURPOSE: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. METHODS: In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. RESULTS: The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748 [0.722–0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). CONCLUSIONS: Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm. Springer International Publishing 2016-08-12 2017 /pmc/articles/PMC5288429/ /pubmed/27517267 http://dx.doi.org/10.1007/s11136-016-1388-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Shiroiwa, T.
Fukuda, T.
Shimozuma, K.
Mouri, M.
Hagiwara, Y.
Doihara, H.
Akabane, H.
Kashiwaba, M.
Watanabe, T.
Ohashi, Y.
Mukai, H.
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
title Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
title_full Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
title_fullStr Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
title_full_unstemmed Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
title_short Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
title_sort long-term health status as measured by eq-5d among patients with metastatic breast cancer: comparison of first-line oral s-1 and taxane therapies in the randomized phase iii select bc trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/
https://www.ncbi.nlm.nih.gov/pubmed/27517267
http://dx.doi.org/10.1007/s11136-016-1388-1
work_keys_str_mv AT shiroiwat longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT fukudat longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT shimozumak longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT mourim longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT hagiwaray longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT doiharah longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT akabaneh longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT kashiwabam longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT watanabet longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT ohashiy longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial
AT mukaih longtermhealthstatusasmeasuredbyeq5damongpatientswithmetastaticbreastcancercomparisonoffirstlineorals1andtaxanetherapiesintherandomizedphaseiiiselectbctrial